The Science for Africa Foundation (SFA Foundation) has announced the establishment of a high-profile Advisory Committee to lead the Cross Pharma Capacity Development Initiative (CPCDI), a bold program aimed at revolutionizing clinical trial capacity on the continent.
The CPCDI, implemented under the Clinical Research and Trials Community (CRTC) program, seeks to address a striking imbalance in clinical trials conducted in Africa. Despite carrying 25% of the global disease burden, Africa hosts less than 4% of clinical trials. The initiative aims to close this gap by building local capacity, fostering cross-sector collaboration, and increasing the visibility of African research capabilities on the global stage.
The newly appointed Advisory Committee, comprising experts from diverse fields, will provide strategic guidance, identify critical gaps, and shape partnerships to ensure the initiative aligns with Africa's healthcare priorities. Members will also advocate for the CPCDI regionally and internationally, enhancing its visibility and securing broad-based support.
Speaking on the initiative, Dr Evelyn Gitau, Chief Scientific Officer at the SFA Foundation, underscored its transformative potential. “By enhancing clinical trial capacity and fostering collaboration, the CPCDI empowers African researchers and institutions to address health challenges with tailored solutions. This is more than an initiative; it’s a commitment to a sustainable future for clinical research in Africa.”
Dr. Allan Pamba, Chair of the Advisory Committee and Executive Vice-President of Africa at Roche Diagnostics, echoed this sentiment. “This initiative is about empowering African institutions and researchers to take charge of the health solutions we need most. It represents a unique opportunity to change the clinical research landscape in Africa,” he said.
The CPCDI aims to dismantle systemic barriers that have historically hindered clinical research in Africa, including complex regulatory environments, limited disease data, and insufficient recognition of local research capabilities. By fostering partnerships and leveraging collective strengths, the initiative seeks to create a resilient ecosystem capable of conducting world-class clinical trials.
In addition to building capacity, the Advisory Committee will validate monitoring and evaluation frameworks to assess the CPCDI’s impact. The initiative is expected to expand patient access to cutting-edge treatments and ensure Africa’s contributions to clinical research are recognized globally.
Ultimately, the CPCDI aspires to position Africa as not just a participant but a leader in global health innovation. By addressing the continent’s unique challenges while advancing global scientific progress, the SFA Foundation is paving the way for Africa to redefine its role in health research and innovation.
Article by RB Reporter
Photo/Google
Comment